© 2020 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Sarcoma
Trabectedin Plus Durvalumab Feasible for Treatment of Soft Tissue Sarcoma
September 21, 2020
Preliminary activity was observed in an unselected group of patients with miscellaneous soft tissue sarcoma treated with trabectedin in combination with durvalumab in the phase 1b TRAMUNE trial. The results presented during the 2020 European Society of Medical Oncology Virtual Congress demonstrate the feasibility of utilizing this combination in soft tissue sarcoma.
Pembrolizumab Extends Progression-Free Survival in Rare Sarcoma Subtypes
September 21, 2020
Prolonged progression-free survival was observed with pembrolizumab monotherapy in patients with selected rare sarcoma subtypes treated in the phase 2 AcSé basket study, according to a presentation during the 2020 European Society of Medical Oncology Virtual Congress.
Ewing Sarcoma May Benefit From Regorafenib Therapy
September 20, 2020
As compared with placebo, regorafenib induced favorable progression-free survival rates at 24 weeks versus placebo in patients with Ewing sarcoma in the phase 2 REGOBONE study. Despite this, the trial failed to meet its primary end point of non-progression at 8 weeks, according to findings presented at the European Society of Medical Oncology Virtual Congress 2020.
Investigators Observe Differences in Toxicity for Sarcoma Due to Dosing
July 14, 2020
Gary K. Schwartz, MD, discusses adverse events seen in patients with metastatic sarcoma participating in the Alliance A091401 trial.
Evaluating the Activity of Trabectedin and Radiotherapy in Sarcoma
June 19, 2020
Alessandro Gronchi, MD, discusses a phase 2 trial of trabectedin and radiotherapy in patients with soft-tissue sarcoma.
Neoadjuvant Blockade Demonstrates Significant Clinical Activity in UPS
June 02, 2020
Christina L. Roland, MD, PhD, discusses the preliminary results of neoadjuvant checkpoint blockade—nivolumab or nivolumab plus ipilimumab—in patients with surgically resectable undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma.
Treatment Options Evolve for Patients With Desmoid Fibromatosis
May 18, 2020
Neeta Somaiah, MD, discusses the evolution of treatment options for patients with a unique sarcoma.
FDA Approves Pomalidomide for Treatment of Kaposi Sarcoma
May 15, 2020
Pomalidomide is now FDA approved for treatment of Kaposi sarcoma under multiple indications.
Patients With Pretreated Sarcoma May Derive Benefit From Various Immunotherapy Combinations
April 15, 2020
Combination therapy strategies involving immune checkpoint inhibitors and a secondary agent have shown promise across sarcoma subtypes, according to analysis of clinical trial data that were presented at the European Society for Medical Oncology Sarcoma & GIST Symposium 2020, held in Milan, Italy.
Cabozantinib May Be a New Therapeutic Option for Ewing Sarcoma and Osteosarcoma
April 03, 2020
Cabozantinib demonstrated antitumor activity as treatment of patients with advanced Ewing sarcoma and osteosarcoma, warranting further investigation for a potential new therapeutic option for this patient population, according to findings from phase II CABONE study.